Author response for "Saxagliptin combined with additional oral antihyperglycemic agents in drug‐naive diabetic patients with high glycosylated hemoglobin: a 24‐week, multicenter, randomized, open‐label, active parallel‐controlled group clinical trial in China (SUCCESS)"